nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—CSF1R—atherosclerosis	0.374	1	CbGaD
Dasatinib—ABCG2—Rosuvastatin—atherosclerosis	0.0336	0.136	CbGbCtD
Dasatinib—ABCG2—Ezetimibe—atherosclerosis	0.0336	0.136	CbGbCtD
Dasatinib—ABCG2—Pravastatin—atherosclerosis	0.0306	0.124	CbGbCtD
Dasatinib—CYP3A5—Rosuvastatin—atherosclerosis	0.0186	0.0752	CbGbCtD
Dasatinib—CYP3A5—Simvastatin—atherosclerosis	0.0173	0.0699	CbGbCtD
Dasatinib—CYP3A5—Pravastatin—atherosclerosis	0.0169	0.0684	CbGbCtD
Dasatinib—CYP3A5—Lovastatin—atherosclerosis	0.0169	0.0684	CbGbCtD
Dasatinib—ABCB1—Ezetimibe—atherosclerosis	0.0121	0.049	CbGbCtD
Dasatinib—ABCB1—Simvastatin—atherosclerosis	0.0113	0.0455	CbGbCtD
Dasatinib—ABCB1—Lovastatin—atherosclerosis	0.011	0.0445	CbGbCtD
Dasatinib—ABCB1—Pravastatin—atherosclerosis	0.011	0.0445	CbGbCtD
Dasatinib—CYP3A4—Rosuvastatin—atherosclerosis	0.00726	0.0293	CbGbCtD
Dasatinib—CYP3A4—Ezetimibe—atherosclerosis	0.00726	0.0293	CbGbCtD
Dasatinib—CYP3A4—Simvastatin—atherosclerosis	0.00675	0.0273	CbGbCtD
Dasatinib—CYP3A4—Lovastatin—atherosclerosis	0.00661	0.0267	CbGbCtD
Dasatinib—CYP3A4—Pravastatin—atherosclerosis	0.00661	0.0267	CbGbCtD
Dasatinib—PDGFRA—penis—atherosclerosis	0.00252	0.033	CbGeAlD
Dasatinib—RIPK2—endothelium—atherosclerosis	0.00134	0.0176	CbGeAlD
Dasatinib—RIPK2—blood vessel—atherosclerosis	0.00124	0.0162	CbGeAlD
Dasatinib—SIK2—connective tissue—atherosclerosis	0.0012	0.0157	CbGeAlD
Dasatinib—SRC—artery—atherosclerosis	0.00114	0.015	CbGeAlD
Dasatinib—EPHB4—endothelium—atherosclerosis	0.00114	0.0149	CbGeAlD
Dasatinib—MAPK14—blood vessel—atherosclerosis	0.0011	0.0145	CbGeAlD
Dasatinib—SRMS—connective tissue—atherosclerosis	0.00109	0.0143	CbGeAlD
Dasatinib—EPHB4—blood vessel—atherosclerosis	0.00105	0.0137	CbGeAlD
Dasatinib—EPHB1—adipose tissue—atherosclerosis	0.00104	0.0137	CbGeAlD
Dasatinib—JAK2—blood vessel—atherosclerosis	0.00104	0.0136	CbGeAlD
Dasatinib—EPHA2—blood vessel—atherosclerosis	0.00103	0.0135	CbGeAlD
Dasatinib—STAT5B—connective tissue—atherosclerosis	0.00101	0.0133	CbGeAlD
Dasatinib—BMX—cardiovascular system—atherosclerosis	0.000993	0.013	CbGeAlD
Dasatinib—SRC—endothelium—atherosclerosis	0.000965	0.0127	CbGeAlD
Dasatinib—TEC—liver—atherosclerosis	0.000931	0.0122	CbGeAlD
Dasatinib—SIK2—adipose tissue—atherosclerosis	0.00092	0.0121	CbGeAlD
Dasatinib—SRC—blood vessel—atherosclerosis	0.00089	0.0117	CbGeAlD
Dasatinib—STAT5B—cardiovascular system—atherosclerosis	0.00088	0.0115	CbGeAlD
Dasatinib—BMX—adipose tissue—atherosclerosis	0.000875	0.0115	CbGeAlD
Dasatinib—LYN—connective tissue—atherosclerosis	0.000823	0.0108	CbGeAlD
Dasatinib—BTK—connective tissue—atherosclerosis	0.000806	0.0106	CbGeAlD
Dasatinib—KIT—endothelium—atherosclerosis	0.000787	0.0103	CbGeAlD
Dasatinib—STAT5B—adipose tissue—atherosclerosis	0.000776	0.0102	CbGeAlD
Dasatinib—TESK1—connective tissue—atherosclerosis	0.000747	0.00979	CbGeAlD
Dasatinib—ZAK—cardiovascular system—atherosclerosis	0.000735	0.00964	CbGeAlD
Dasatinib—EPHB1—liver—atherosclerosis	0.000731	0.00958	CbGeAlD
Dasatinib—KIT—blood vessel—atherosclerosis	0.000726	0.00951	CbGeAlD
Dasatinib—EPHA3—adipose tissue—atherosclerosis	0.000717	0.0094	CbGeAlD
Dasatinib—PDGFRB—blood vessel—atherosclerosis	0.000709	0.00929	CbGeAlD
Dasatinib—SIK3—adipose tissue—atherosclerosis	0.000698	0.00914	CbGeAlD
Dasatinib—CSK—connective tissue—atherosclerosis	0.000684	0.00897	CbGeAlD
Dasatinib—ZAK—adipose tissue—atherosclerosis	0.000648	0.0085	CbGeAlD
Dasatinib—SIK2—liver—atherosclerosis	0.000645	0.00846	CbGeAlD
Dasatinib—RIPK2—connective tissue—atherosclerosis	0.000635	0.00833	CbGeAlD
Dasatinib—FRK—liver—atherosclerosis	0.000629	0.00824	CbGeAlD
Dasatinib—BMPR1B—adipose tissue—atherosclerosis	0.000622	0.00815	CbGeAlD
Dasatinib—SIK1—connective tissue—atherosclerosis	0.00062	0.00813	CbGeAlD
Dasatinib—BTK—adipose tissue—atherosclerosis	0.000619	0.00811	CbGeAlD
Dasatinib—TNK2—adipose tissue—atherosclerosis	0.00061	0.00799	CbGeAlD
Dasatinib—ERBB3—connective tissue—atherosclerosis	0.000608	0.00797	CbGeAlD
Dasatinib—MAP3K2—connective tissue—atherosclerosis	0.000602	0.00789	CbGeAlD
Dasatinib—CSK—cardiovascular system—atherosclerosis	0.000596	0.00781	CbGeAlD
Dasatinib—TESK1—adipose tissue—atherosclerosis	0.000573	0.00751	CbGeAlD
Dasatinib—MAPK14—connective tissue—atherosclerosis	0.000566	0.00742	CbGeAlD
Dasatinib—STK36—adipose tissue—atherosclerosis	0.000564	0.00739	CbGeAlD
Dasatinib—RIPK2—cardiovascular system—atherosclerosis	0.000553	0.00724	CbGeAlD
Dasatinib—LIMK2—adipose tissue—atherosclerosis	0.000545	0.00715	CbGeAlD
Dasatinib—STAT5B—liver—atherosclerosis	0.000544	0.00713	CbGeAlD
Dasatinib—EPHB4—connective tissue—atherosclerosis	0.000537	0.00703	CbGeAlD
Dasatinib—JAK2—connective tissue—atherosclerosis	0.000533	0.00699	CbGeAlD
Dasatinib—STK35—adipose tissue—atherosclerosis	0.000529	0.00693	CbGeAlD
Dasatinib—FYN—connective tissue—atherosclerosis	0.000526	0.00689	CbGeAlD
Dasatinib—CSK—adipose tissue—atherosclerosis	0.000525	0.00688	CbGeAlD
Dasatinib—HCK—adipose tissue—atherosclerosis	0.000518	0.00679	CbGeAlD
Dasatinib—ABL2—adipose tissue—atherosclerosis	0.000515	0.00675	CbGeAlD
Dasatinib—MAPK14—cardiovascular system—atherosclerosis	0.000493	0.00646	CbGeAlD
Dasatinib—FGR—cardiovascular system—atherosclerosis	0.000491	0.00643	CbGeAlD
Dasatinib—SIK3—liver—atherosclerosis	0.000489	0.00641	CbGeAlD
Dasatinib—RIPK2—adipose tissue—atherosclerosis	0.000487	0.00639	CbGeAlD
Dasatinib—SIK1—adipose tissue—atherosclerosis	0.000476	0.00624	CbGeAlD
Dasatinib—YES1—connective tissue—atherosclerosis	0.000474	0.00622	CbGeAlD
Dasatinib—EPHA4—adipose tissue—atherosclerosis	0.000471	0.00618	CbGeAlD
Dasatinib—EPHB4—cardiovascular system—atherosclerosis	0.000467	0.00612	CbGeAlD
Dasatinib—ERBB3—adipose tissue—atherosclerosis	0.000467	0.00611	CbGeAlD
Dasatinib—PDGFRA—connective tissue—atherosclerosis	0.000465	0.0061	CbGeAlD
Dasatinib—JAK2—cardiovascular system—atherosclerosis	0.000464	0.00608	CbGeAlD
Dasatinib—MAP3K2—adipose tissue—atherosclerosis	0.000462	0.00606	CbGeAlD
Dasatinib—EPHA2—cardiovascular system—atherosclerosis	0.000458	0.006	CbGeAlD
Dasatinib—FYN—cardiovascular system—atherosclerosis	0.000457	0.00599	CbGeAlD
Dasatinib—SRC—connective tissue—atherosclerosis	0.000456	0.00598	CbGeAlD
Dasatinib—ZAK—liver—atherosclerosis	0.000455	0.00596	CbGeAlD
Dasatinib—MAP3K3—cardiovascular system—atherosclerosis	0.000447	0.00586	CbGeAlD
Dasatinib—LYN—liver—atherosclerosis	0.000443	0.0058	CbGeAlD
Dasatinib—MAPK14—adipose tissue—atherosclerosis	0.000434	0.00569	CbGeAlD
Dasatinib—BTK—liver—atherosclerosis	0.000434	0.00569	CbGeAlD
Dasatinib—FGR—adipose tissue—atherosclerosis	0.000433	0.00567	CbGeAlD
Dasatinib—LCK—adipose tissue—atherosclerosis	0.000433	0.00567	CbGeAlD
Dasatinib—TNK2—liver—atherosclerosis	0.000428	0.0056	CbGeAlD
Dasatinib—FMO3—adipose tissue—atherosclerosis	0.000418	0.00548	CbGeAlD
Dasatinib—EPHB4—adipose tissue—atherosclerosis	0.000412	0.0054	CbGeAlD
Dasatinib—CSF1R—connective tissue—atherosclerosis	0.00041	0.00537	CbGeAlD
Dasatinib—JAK2—adipose tissue—atherosclerosis	0.000409	0.00536	CbGeAlD
Dasatinib—PDGFRA—cardiovascular system—atherosclerosis	0.000405	0.00531	CbGeAlD
Dasatinib—EPHA2—adipose tissue—atherosclerosis	0.000404	0.0053	CbGeAlD
Dasatinib—FYN—adipose tissue—atherosclerosis	0.000403	0.00529	CbGeAlD
Dasatinib—TESK1—liver—atherosclerosis	0.000402	0.00527	CbGeAlD
Dasatinib—SRC—cardiovascular system—atherosclerosis	0.000397	0.0052	CbGeAlD
Dasatinib—STK36—liver—atherosclerosis	0.000396	0.00519	CbGeAlD
Dasatinib—MAP3K3—adipose tissue—atherosclerosis	0.000394	0.00517	CbGeAlD
Dasatinib—MAP4K5—adipose tissue—atherosclerosis	0.000394	0.00517	CbGeAlD
Dasatinib—LIMK2—liver—atherosclerosis	0.000382	0.00501	CbGeAlD
Dasatinib—EPHB6—adipose tissue—atherosclerosis	0.000377	0.00494	CbGeAlD
Dasatinib—KIT—connective tissue—atherosclerosis	0.000372	0.00488	CbGeAlD
Dasatinib—STK35—liver—atherosclerosis	0.000371	0.00486	CbGeAlD
Dasatinib—CSK—liver—atherosclerosis	0.000368	0.00483	CbGeAlD
Dasatinib—MAP2K5—cardiovascular system—atherosclerosis	0.000365	0.00479	CbGeAlD
Dasatinib—YES1—adipose tissue—atherosclerosis	0.000364	0.00477	CbGeAlD
Dasatinib—HCK—liver—atherosclerosis	0.000364	0.00476	CbGeAlD
Dasatinib—PDGFRB—connective tissue—atherosclerosis	0.000363	0.00476	CbGeAlD
Dasatinib—ABL2—liver—atherosclerosis	0.000361	0.00474	CbGeAlD
Dasatinib—PDGFRA—adipose tissue—atherosclerosis	0.000357	0.00468	CbGeAlD
Dasatinib—CSF1R—cardiovascular system—atherosclerosis	0.000356	0.00467	CbGeAlD
Dasatinib—SRC—adipose tissue—atherosclerosis	0.00035	0.00459	CbGeAlD
Dasatinib—RIPK2—liver—atherosclerosis	0.000342	0.00448	CbGeAlD
Dasatinib—SIK1—liver—atherosclerosis	0.000334	0.00437	CbGeAlD
Dasatinib—ERBB3—liver—atherosclerosis	0.000327	0.00429	CbGeAlD
Dasatinib—MAP3K2—liver—atherosclerosis	0.000324	0.00425	CbGeAlD
Dasatinib—ABL1—connective tissue—atherosclerosis	0.000324	0.00424	CbGeAlD
Dasatinib—KIT—cardiovascular system—atherosclerosis	0.000324	0.00424	CbGeAlD
Dasatinib—MAP2K5—adipose tissue—atherosclerosis	0.000322	0.00422	CbGeAlD
Dasatinib—PDGFRB—cardiovascular system—atherosclerosis	0.000316	0.00414	CbGeAlD
Dasatinib—CSF1R—adipose tissue—atherosclerosis	0.000314	0.00412	CbGeAlD
Dasatinib—MAPK14—liver—atherosclerosis	0.000305	0.00399	CbGeAlD
Dasatinib—FGR—liver—atherosclerosis	0.000303	0.00398	CbGeAlD
Dasatinib—LCK—liver—atherosclerosis	0.000303	0.00398	CbGeAlD
Dasatinib—FMO3—liver—atherosclerosis	0.000293	0.00384	CbGeAlD
Dasatinib—EPHB4—liver—atherosclerosis	0.000289	0.00379	CbGeAlD
Dasatinib—JAK2—liver—atherosclerosis	0.000287	0.00376	CbGeAlD
Dasatinib—KIT—adipose tissue—atherosclerosis	0.000285	0.00374	CbGeAlD
Dasatinib—EPHA2—liver—atherosclerosis	0.000283	0.00371	CbGeAlD
Dasatinib—FYN—liver—atherosclerosis	0.000283	0.00371	CbGeAlD
Dasatinib—ABL1—cardiovascular system—atherosclerosis	0.000282	0.00369	CbGeAlD
Dasatinib—PDGFRB—adipose tissue—atherosclerosis	0.000279	0.00365	CbGeAlD
Dasatinib—MAP4K5—liver—atherosclerosis	0.000276	0.00362	CbGeAlD
Dasatinib—MAP3K3—liver—atherosclerosis	0.000276	0.00362	CbGeAlD
Dasatinib—CYP1B1—connective tissue—atherosclerosis	0.000274	0.00359	CbGeAlD
Dasatinib—Oedema peripheral—Niacin—atherosclerosis	0.000261	0.002	CcSEcCtD
Dasatinib—Hepatitis—Pravastatin—atherosclerosis	0.000261	0.002	CcSEcCtD
Dasatinib—Confusional state—Rosuvastatin—atherosclerosis	0.000261	0.002	CcSEcCtD
Dasatinib—Chills—Simvastatin—atherosclerosis	0.000259	0.00199	CcSEcCtD
Dasatinib—Muscle spasms—Lovastatin—atherosclerosis	0.000258	0.00198	CcSEcCtD
Dasatinib—Infection—Rosuvastatin—atherosclerosis	0.000257	0.00197	CcSEcCtD
Dasatinib—Visual impairment—Niacin—atherosclerosis	0.000255	0.00196	CcSEcCtD
Dasatinib—YES1—liver—atherosclerosis	0.000255	0.00335	CbGeAlD
Dasatinib—Alopecia—Simvastatin—atherosclerosis	0.000255	0.00196	CcSEcCtD
Dasatinib—Nervous system disorder—Rosuvastatin—atherosclerosis	0.000254	0.00195	CcSEcCtD
Dasatinib—Muscle spasms—Ezetimibe—atherosclerosis	0.000253	0.00194	CcSEcCtD
Dasatinib—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.000253	0.00194	CcSEcCtD
Dasatinib—Vision blurred—Lovastatin—atherosclerosis	0.000253	0.00194	CcSEcCtD
Dasatinib—Mental disorder—Simvastatin—atherosclerosis	0.000253	0.00194	CcSEcCtD
Dasatinib—Tremor—Lovastatin—atherosclerosis	0.000252	0.00193	CcSEcCtD
Dasatinib—Visual impairment—Pravastatin—atherosclerosis	0.000251	0.00193	CcSEcCtD
Dasatinib—Erythema—Simvastatin—atherosclerosis	0.000251	0.00193	CcSEcCtD
Dasatinib—PDGFRA—liver—atherosclerosis	0.00025	0.00328	CbGeAlD
Dasatinib—Ill-defined disorder—Lovastatin—atherosclerosis	0.000249	0.00191	CcSEcCtD
Dasatinib—ABL1—adipose tissue—atherosclerosis	0.000249	0.00326	CbGeAlD
Dasatinib—Eye disorder—Niacin—atherosclerosis	0.000248	0.0019	CcSEcCtD
Dasatinib—Tinnitus—Niacin—atherosclerosis	0.000247	0.00189	CcSEcCtD
Dasatinib—Erythema multiforme—Pravastatin—atherosclerosis	0.000247	0.00189	CcSEcCtD
Dasatinib—Dysgeusia—Simvastatin—atherosclerosis	0.000246	0.00189	CcSEcCtD
Dasatinib—Flushing—Niacin—atherosclerosis	0.000246	0.00189	CcSEcCtD
Dasatinib—SRC—liver—atherosclerosis	0.000246	0.00322	CbGeAlD
Dasatinib—Ill-defined disorder—Ezetimibe—atherosclerosis	0.000244	0.00187	CcSEcCtD
Dasatinib—Anaemia—Ezetimibe—atherosclerosis	0.000243	0.00187	CcSEcCtD
Dasatinib—Tinnitus—Pravastatin—atherosclerosis	0.000243	0.00187	CcSEcCtD
Dasatinib—Malaise—Lovastatin—atherosclerosis	0.000242	0.00186	CcSEcCtD
Dasatinib—Flushing—Pravastatin—atherosclerosis	0.000242	0.00186	CcSEcCtD
Dasatinib—Cardiac disorder—Pravastatin—atherosclerosis	0.000242	0.00186	CcSEcCtD
Dasatinib—Muscle spasms—Simvastatin—atherosclerosis	0.000242	0.00185	CcSEcCtD
Dasatinib—Vertigo—Lovastatin—atherosclerosis	0.000241	0.00185	CcSEcCtD
Dasatinib—Angiopathy—Niacin—atherosclerosis	0.00024	0.00184	CcSEcCtD
Dasatinib—CYP1B1—cardiovascular system—atherosclerosis	0.000239	0.00313	CbGeAlD
Dasatinib—Chills—Niacin—atherosclerosis	0.000238	0.00182	CcSEcCtD
Dasatinib—Malaise—Ezetimibe—atherosclerosis	0.000238	0.00182	CcSEcCtD
Dasatinib—Vision blurred—Simvastatin—atherosclerosis	0.000237	0.00182	CcSEcCtD
Dasatinib—Arrhythmia—Niacin—atherosclerosis	0.000237	0.00182	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000236	0.00181	CcSEcCtD
Dasatinib—Tremor—Simvastatin—atherosclerosis	0.000235	0.00181	CcSEcCtD
Dasatinib—Alopecia—Niacin—atherosclerosis	0.000234	0.0018	CcSEcCtD
Dasatinib—Chills—Pravastatin—atherosclerosis	0.000234	0.0018	CcSEcCtD
Dasatinib—Insomnia—Rosuvastatin—atherosclerosis	0.000234	0.00179	CcSEcCtD
Dasatinib—Ill-defined disorder—Simvastatin—atherosclerosis	0.000233	0.00179	CcSEcCtD
Dasatinib—Arrhythmia—Pravastatin—atherosclerosis	0.000233	0.00179	CcSEcCtD
Dasatinib—Palpitations—Ezetimibe—atherosclerosis	0.000233	0.00179	CcSEcCtD
Dasatinib—Anaemia—Simvastatin—atherosclerosis	0.000232	0.00178	CcSEcCtD
Dasatinib—Erythema—Niacin—atherosclerosis	0.000231	0.00177	CcSEcCtD
Dasatinib—Malnutrition—Niacin—atherosclerosis	0.000231	0.00177	CcSEcCtD
Dasatinib—Alopecia—Pravastatin—atherosclerosis	0.000231	0.00177	CcSEcCtD
Dasatinib—Cough—Ezetimibe—atherosclerosis	0.00023	0.00176	CcSEcCtD
Dasatinib—Myalgia—Lovastatin—atherosclerosis	0.000229	0.00175	CcSEcCtD
Dasatinib—Chest pain—Lovastatin—atherosclerosis	0.000229	0.00175	CcSEcCtD
Dasatinib—Arthralgia—Lovastatin—atherosclerosis	0.000229	0.00175	CcSEcCtD
Dasatinib—Anxiety—Lovastatin—atherosclerosis	0.000228	0.00175	CcSEcCtD
Dasatinib—Dyspepsia—Rosuvastatin—atherosclerosis	0.000228	0.00175	CcSEcCtD
Dasatinib—Hypertension—Ezetimibe—atherosclerosis	0.000227	0.00174	CcSEcCtD
Dasatinib—Malaise—Simvastatin—atherosclerosis	0.000227	0.00174	CcSEcCtD
Dasatinib—Discomfort—Lovastatin—atherosclerosis	0.000226	0.00173	CcSEcCtD
Dasatinib—MAP2K5—liver—atherosclerosis	0.000226	0.00296	CbGeAlD
Dasatinib—Vertigo—Simvastatin—atherosclerosis	0.000226	0.00173	CcSEcCtD
Dasatinib—Arthralgia—Ezetimibe—atherosclerosis	0.000224	0.00172	CcSEcCtD
Dasatinib—Chest pain—Ezetimibe—atherosclerosis	0.000224	0.00172	CcSEcCtD
Dasatinib—Myalgia—Ezetimibe—atherosclerosis	0.000224	0.00172	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000223	0.00171	CcSEcCtD
Dasatinib—Dysgeusia—Pravastatin—atherosclerosis	0.000222	0.00171	CcSEcCtD
Dasatinib—Muscle spasms—Niacin—atherosclerosis	0.000222	0.0017	CcSEcCtD
Dasatinib—Discomfort—Ezetimibe—atherosclerosis	0.000222	0.0017	CcSEcCtD
Dasatinib—Pain—Rosuvastatin—atherosclerosis	0.000221	0.0017	CcSEcCtD
Dasatinib—Constipation—Rosuvastatin—atherosclerosis	0.000221	0.0017	CcSEcCtD
Dasatinib—Confusional state—Lovastatin—atherosclerosis	0.000221	0.00169	CcSEcCtD
Dasatinib—CSF1R—liver—atherosclerosis	0.00022	0.00289	CbGeAlD
Dasatinib—Muscle spasms—Pravastatin—atherosclerosis	0.000218	0.00167	CcSEcCtD
Dasatinib—Infection—Lovastatin—atherosclerosis	0.000218	0.00167	CcSEcCtD
Dasatinib—Vision blurred—Niacin—atherosclerosis	0.000217	0.00167	CcSEcCtD
Dasatinib—Confusional state—Ezetimibe—atherosclerosis	0.000217	0.00166	CcSEcCtD
Dasatinib—Thrombocytopenia—Lovastatin—atherosclerosis	0.000215	0.00165	CcSEcCtD
Dasatinib—Vision blurred—Pravastatin—atherosclerosis	0.000214	0.00164	CcSEcCtD
Dasatinib—Arthralgia—Simvastatin—atherosclerosis	0.000214	0.00164	CcSEcCtD
Dasatinib—Chest pain—Simvastatin—atherosclerosis	0.000214	0.00164	CcSEcCtD
Dasatinib—Myalgia—Simvastatin—atherosclerosis	0.000214	0.00164	CcSEcCtD
Dasatinib—Infection—Ezetimibe—atherosclerosis	0.000214	0.00164	CcSEcCtD
Dasatinib—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000213	0.00163	CcSEcCtD
Dasatinib—Anxiety—Simvastatin—atherosclerosis	0.000213	0.00163	CcSEcCtD
Dasatinib—Tremor—Pravastatin—atherosclerosis	0.000213	0.00163	CcSEcCtD
Dasatinib—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000211	0.00162	CcSEcCtD
Dasatinib—Discomfort—Simvastatin—atherosclerosis	0.000211	0.00162	CcSEcCtD
Dasatinib—Nervous system disorder—Ezetimibe—atherosclerosis	0.000211	0.00162	CcSEcCtD
Dasatinib—Ill-defined disorder—Pravastatin—atherosclerosis	0.000211	0.00162	CcSEcCtD
Dasatinib—Thrombocytopenia—Ezetimibe—atherosclerosis	0.00021	0.00161	CcSEcCtD
Dasatinib—CYP1B1—adipose tissue—atherosclerosis	0.00021	0.00276	CbGeAlD
Dasatinib—Anaemia—Pravastatin—atherosclerosis	0.00021	0.00161	CcSEcCtD
Dasatinib—Anorexia—Lovastatin—atherosclerosis	0.000209	0.0016	CcSEcCtD
Dasatinib—Skin disorder—Ezetimibe—atherosclerosis	0.000209	0.0016	CcSEcCtD
Dasatinib—Vertigo—Niacin—atherosclerosis	0.000207	0.00159	CcSEcCtD
Dasatinib—Syncope—Niacin—atherosclerosis	0.000207	0.00159	CcSEcCtD
Dasatinib—Confusional state—Simvastatin—atherosclerosis	0.000207	0.00159	CcSEcCtD
Dasatinib—Urticaria—Rosuvastatin—atherosclerosis	0.000205	0.00158	CcSEcCtD
Dasatinib—Oedema—Simvastatin—atherosclerosis	0.000205	0.00157	CcSEcCtD
Dasatinib—Malaise—Pravastatin—atherosclerosis	0.000205	0.00157	CcSEcCtD
Dasatinib—Abdominal pain—Rosuvastatin—atherosclerosis	0.000204	0.00157	CcSEcCtD
Dasatinib—Vertigo—Pravastatin—atherosclerosis	0.000204	0.00156	CcSEcCtD
Dasatinib—Palpitations—Niacin—atherosclerosis	0.000204	0.00156	CcSEcCtD
Dasatinib—Infection—Simvastatin—atherosclerosis	0.000204	0.00156	CcSEcCtD
Dasatinib—Loss of consciousness—Niacin—atherosclerosis	0.000203	0.00155	CcSEcCtD
Dasatinib—Cough—Niacin—atherosclerosis	0.000201	0.00154	CcSEcCtD
Dasatinib—Thrombocytopenia—Simvastatin—atherosclerosis	0.000201	0.00154	CcSEcCtD
Dasatinib—KIT—liver—atherosclerosis	0.0002	0.00262	CbGeAlD
Dasatinib—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.0002	0.00153	CcSEcCtD
Dasatinib—Insomnia—Lovastatin—atherosclerosis	0.000198	0.00152	CcSEcCtD
Dasatinib—Cough—Pravastatin—atherosclerosis	0.000198	0.00152	CcSEcCtD
Dasatinib—ABCB1—blood vessel—atherosclerosis	0.000196	0.00257	CbGeAlD
Dasatinib—Arthralgia—Niacin—atherosclerosis	0.000196	0.00151	CcSEcCtD
Dasatinib—Myalgia—Niacin—atherosclerosis	0.000196	0.00151	CcSEcCtD
Dasatinib—Hypertension—Pravastatin—atherosclerosis	0.000196	0.0015	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000196	0.0015	CcSEcCtD
Dasatinib—PDGFRB—liver—atherosclerosis	0.000196	0.00256	CbGeAlD
Dasatinib—Anorexia—Simvastatin—atherosclerosis	0.000195	0.0015	CcSEcCtD
Dasatinib—Dyspnoea—Lovastatin—atherosclerosis	0.000195	0.0015	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000195	0.0015	CcSEcCtD
Dasatinib—Insomnia—Ezetimibe—atherosclerosis	0.000194	0.00149	CcSEcCtD
Dasatinib—Chest pain—Pravastatin—atherosclerosis	0.000193	0.00148	CcSEcCtD
Dasatinib—Myalgia—Pravastatin—atherosclerosis	0.000193	0.00148	CcSEcCtD
Dasatinib—Arthralgia—Pravastatin—atherosclerosis	0.000193	0.00148	CcSEcCtD
Dasatinib—Dyspepsia—Lovastatin—atherosclerosis	0.000193	0.00148	CcSEcCtD
Dasatinib—Anxiety—Pravastatin—atherosclerosis	0.000193	0.00148	CcSEcCtD
Dasatinib—Dyspnoea—Ezetimibe—atherosclerosis	0.000192	0.00147	CcSEcCtD
Dasatinib—Discomfort—Pravastatin—atherosclerosis	0.000191	0.00147	CcSEcCtD
Dasatinib—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000191	0.00146	CcSEcCtD
Dasatinib—Decreased appetite—Lovastatin—atherosclerosis	0.000191	0.00146	CcSEcCtD
Dasatinib—Dyspepsia—Ezetimibe—atherosclerosis	0.000189	0.00145	CcSEcCtD
Dasatinib—Fatigue—Lovastatin—atherosclerosis	0.000189	0.00145	CcSEcCtD
Dasatinib—Oedema—Niacin—atherosclerosis	0.000188	0.00144	CcSEcCtD
Dasatinib—Pain—Lovastatin—atherosclerosis	0.000187	0.00144	CcSEcCtD
Dasatinib—Constipation—Lovastatin—atherosclerosis	0.000187	0.00144	CcSEcCtD
Dasatinib—Confusional state—Pravastatin—atherosclerosis	0.000187	0.00143	CcSEcCtD
Dasatinib—Decreased appetite—Ezetimibe—atherosclerosis	0.000187	0.00143	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000187	0.00143	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000186	0.00142	CcSEcCtD
Dasatinib—Asthenia—Rosuvastatin—atherosclerosis	0.000186	0.00142	CcSEcCtD
Dasatinib—Insomnia—Simvastatin—atherosclerosis	0.000185	0.00142	CcSEcCtD
Dasatinib—Oedema—Pravastatin—atherosclerosis	0.000185	0.00142	CcSEcCtD
Dasatinib—Fatigue—Ezetimibe—atherosclerosis	0.000185	0.00142	CcSEcCtD
Dasatinib—Shock—Niacin—atherosclerosis	0.000185	0.00142	CcSEcCtD
Dasatinib—Infection—Pravastatin—atherosclerosis	0.000184	0.00141	CcSEcCtD
Dasatinib—Constipation—Ezetimibe—atherosclerosis	0.000184	0.00141	CcSEcCtD
Dasatinib—Pain—Ezetimibe—atherosclerosis	0.000184	0.00141	CcSEcCtD
Dasatinib—Tachycardia—Niacin—atherosclerosis	0.000184	0.00141	CcSEcCtD
Dasatinib—Pruritus—Rosuvastatin—atherosclerosis	0.000183	0.0014	CcSEcCtD
Dasatinib—Skin disorder—Niacin—atherosclerosis	0.000183	0.0014	CcSEcCtD
Dasatinib—Dyspnoea—Simvastatin—atherosclerosis	0.000183	0.0014	CcSEcCtD
Dasatinib—Hyperhidrosis—Niacin—atherosclerosis	0.000182	0.0014	CcSEcCtD
Dasatinib—Thrombocytopenia—Pravastatin—atherosclerosis	0.000181	0.00139	CcSEcCtD
Dasatinib—Feeling abnormal—Lovastatin—atherosclerosis	0.000181	0.00139	CcSEcCtD
Dasatinib—Dyspepsia—Simvastatin—atherosclerosis	0.00018	0.00138	CcSEcCtD
Dasatinib—Anorexia—Niacin—atherosclerosis	0.000179	0.00138	CcSEcCtD
Dasatinib—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000179	0.00137	CcSEcCtD
Dasatinib—Hyperhidrosis—Pravastatin—atherosclerosis	0.000179	0.00137	CcSEcCtD
Dasatinib—Decreased appetite—Simvastatin—atherosclerosis	0.000178	0.00137	CcSEcCtD
Dasatinib—Feeling abnormal—Ezetimibe—atherosclerosis	0.000177	0.00136	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000177	0.00136	CcSEcCtD
Dasatinib—Diarrhoea—Rosuvastatin—atherosclerosis	0.000177	0.00136	CcSEcCtD
Dasatinib—Fatigue—Simvastatin—atherosclerosis	0.000177	0.00136	CcSEcCtD
Dasatinib—Anorexia—Pravastatin—atherosclerosis	0.000177	0.00136	CcSEcCtD
Dasatinib—Hypotension—Niacin—atherosclerosis	0.000176	0.00135	CcSEcCtD
Dasatinib—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000176	0.00135	CcSEcCtD
Dasatinib—Constipation—Simvastatin—atherosclerosis	0.000175	0.00134	CcSEcCtD
Dasatinib—Pain—Simvastatin—atherosclerosis	0.000175	0.00134	CcSEcCtD
Dasatinib—ABL1—liver—atherosclerosis	0.000174	0.00228	CbGeAlD
Dasatinib—Urticaria—Lovastatin—atherosclerosis	0.000174	0.00134	CcSEcCtD
Dasatinib—Body temperature increased—Lovastatin—atherosclerosis	0.000173	0.00133	CcSEcCtD
Dasatinib—Abdominal pain—Lovastatin—atherosclerosis	0.000173	0.00133	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000172	0.00132	CcSEcCtD
Dasatinib—Dizziness—Rosuvastatin—atherosclerosis	0.000171	0.00131	CcSEcCtD
Dasatinib—Urticaria—Ezetimibe—atherosclerosis	0.000171	0.00131	CcSEcCtD
Dasatinib—Insomnia—Niacin—atherosclerosis	0.00017	0.00131	CcSEcCtD
Dasatinib—Body temperature increased—Ezetimibe—atherosclerosis	0.00017	0.0013	CcSEcCtD
Dasatinib—Abdominal pain—Ezetimibe—atherosclerosis	0.00017	0.0013	CcSEcCtD
Dasatinib—Feeling abnormal—Simvastatin—atherosclerosis	0.000169	0.0013	CcSEcCtD
Dasatinib—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000169	0.0013	CcSEcCtD
Dasatinib—Dyspnoea—Niacin—atherosclerosis	0.000168	0.00129	CcSEcCtD
Dasatinib—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000168	0.00129	CcSEcCtD
Dasatinib—Insomnia—Pravastatin—atherosclerosis	0.000168	0.00129	CcSEcCtD
Dasatinib—Somnolence—Niacin—atherosclerosis	0.000167	0.00128	CcSEcCtD
Dasatinib—Dyspepsia—Niacin—atherosclerosis	0.000166	0.00127	CcSEcCtD
Dasatinib—Dyspnoea—Pravastatin—atherosclerosis	0.000165	0.00127	CcSEcCtD
Dasatinib—Decreased appetite—Niacin—atherosclerosis	0.000164	0.00126	CcSEcCtD
Dasatinib—Dyspepsia—Pravastatin—atherosclerosis	0.000163	0.00125	CcSEcCtD
Dasatinib—Rash—Rosuvastatin—atherosclerosis	0.000163	0.00125	CcSEcCtD
Dasatinib—Dermatitis—Rosuvastatin—atherosclerosis	0.000163	0.00125	CcSEcCtD
Dasatinib—Urticaria—Simvastatin—atherosclerosis	0.000163	0.00125	CcSEcCtD
Dasatinib—Gastrointestinal disorder—Niacin—atherosclerosis	0.000163	0.00125	CcSEcCtD
Dasatinib—Abdominal pain—Simvastatin—atherosclerosis	0.000162	0.00124	CcSEcCtD
Dasatinib—Body temperature increased—Simvastatin—atherosclerosis	0.000162	0.00124	CcSEcCtD
Dasatinib—Headache—Rosuvastatin—atherosclerosis	0.000162	0.00124	CcSEcCtD
Dasatinib—Hypersensitivity—Lovastatin—atherosclerosis	0.000161	0.00124	CcSEcCtD
Dasatinib—Decreased appetite—Pravastatin—atherosclerosis	0.000161	0.00124	CcSEcCtD
Dasatinib—Pain—Niacin—atherosclerosis	0.000161	0.00123	CcSEcCtD
Dasatinib—Fatigue—Pravastatin—atherosclerosis	0.00016	0.00123	CcSEcCtD
Dasatinib—Constipation—Pravastatin—atherosclerosis	0.000159	0.00122	CcSEcCtD
Dasatinib—Pain—Pravastatin—atherosclerosis	0.000159	0.00122	CcSEcCtD
Dasatinib—Hypersensitivity—Ezetimibe—atherosclerosis	0.000158	0.00121	CcSEcCtD
Dasatinib—Asthenia—Lovastatin—atherosclerosis	0.000157	0.00121	CcSEcCtD
Dasatinib—ABCG2—adipose tissue—atherosclerosis	0.000157	0.00205	CbGeAlD
Dasatinib—Pruritus—Lovastatin—atherosclerosis	0.000155	0.00119	CcSEcCtD
Dasatinib—Asthenia—Ezetimibe—atherosclerosis	0.000154	0.00118	CcSEcCtD
Dasatinib—Gastrointestinal pain—Niacin—atherosclerosis	0.000154	0.00118	CcSEcCtD
Dasatinib—Nausea—Rosuvastatin—atherosclerosis	0.000154	0.00118	CcSEcCtD
Dasatinib—Feeling abnormal—Pravastatin—atherosclerosis	0.000153	0.00117	CcSEcCtD
Dasatinib—Pruritus—Ezetimibe—atherosclerosis	0.000152	0.00117	CcSEcCtD
Dasatinib—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000152	0.00116	CcSEcCtD
Dasatinib—Hypersensitivity—Simvastatin—atherosclerosis	0.000151	0.00116	CcSEcCtD
Dasatinib—Diarrhoea—Lovastatin—atherosclerosis	0.00015	0.00115	CcSEcCtD
Dasatinib—Urticaria—Niacin—atherosclerosis	0.00015	0.00115	CcSEcCtD
Dasatinib—Abdominal pain—Niacin—atherosclerosis	0.000149	0.00114	CcSEcCtD
Dasatinib—Body temperature increased—Niacin—atherosclerosis	0.000149	0.00114	CcSEcCtD
Dasatinib—CYP1A1—adipose tissue—atherosclerosis	0.000149	0.00195	CbGeAlD
Dasatinib—CYP1B1—liver—atherosclerosis	0.000148	0.00193	CbGeAlD
Dasatinib—Urticaria—Pravastatin—atherosclerosis	0.000147	0.00113	CcSEcCtD
Dasatinib—Asthenia—Simvastatin—atherosclerosis	0.000147	0.00113	CcSEcCtD
Dasatinib—Diarrhoea—Ezetimibe—atherosclerosis	0.000147	0.00113	CcSEcCtD
Dasatinib—Body temperature increased—Pravastatin—atherosclerosis	0.000147	0.00112	CcSEcCtD
Dasatinib—Abdominal pain—Pravastatin—atherosclerosis	0.000147	0.00112	CcSEcCtD
Dasatinib—CYP3A5—adipose tissue—atherosclerosis	0.000145	0.00191	CbGeAlD
Dasatinib—Pruritus—Simvastatin—atherosclerosis	0.000145	0.00111	CcSEcCtD
Dasatinib—Dizziness—Lovastatin—atherosclerosis	0.000145	0.00111	CcSEcCtD
Dasatinib—Dizziness—Ezetimibe—atherosclerosis	0.000142	0.00109	CcSEcCtD
Dasatinib—Diarrhoea—Simvastatin—atherosclerosis	0.00014	0.00108	CcSEcCtD
Dasatinib—Vomiting—Lovastatin—atherosclerosis	0.000139	0.00107	CcSEcCtD
Dasatinib—Hypersensitivity—Niacin—atherosclerosis	0.000139	0.00106	CcSEcCtD
Dasatinib—Rash—Lovastatin—atherosclerosis	0.000138	0.00106	CcSEcCtD
Dasatinib—Dermatitis—Lovastatin—atherosclerosis	0.000138	0.00106	CcSEcCtD
Dasatinib—Headache—Lovastatin—atherosclerosis	0.000137	0.00105	CcSEcCtD
Dasatinib—Vomiting—Ezetimibe—atherosclerosis	0.000137	0.00105	CcSEcCtD
Dasatinib—Hypersensitivity—Pravastatin—atherosclerosis	0.000137	0.00105	CcSEcCtD
Dasatinib—Dizziness—Simvastatin—atherosclerosis	0.000136	0.00104	CcSEcCtD
Dasatinib—Rash—Ezetimibe—atherosclerosis	0.000136	0.00104	CcSEcCtD
Dasatinib—Dermatitis—Ezetimibe—atherosclerosis	0.000135	0.00104	CcSEcCtD
Dasatinib—Asthenia—Niacin—atherosclerosis	0.000135	0.00104	CcSEcCtD
Dasatinib—Headache—Ezetimibe—atherosclerosis	0.000135	0.00103	CcSEcCtD
Dasatinib—Pruritus—Niacin—atherosclerosis	0.000133	0.00102	CcSEcCtD
Dasatinib—Asthenia—Pravastatin—atherosclerosis	0.000133	0.00102	CcSEcCtD
Dasatinib—Pruritus—Pravastatin—atherosclerosis	0.000131	0.00101	CcSEcCtD
Dasatinib—Vomiting—Simvastatin—atherosclerosis	0.00013	0.001	CcSEcCtD
Dasatinib—Nausea—Lovastatin—atherosclerosis	0.00013	0.000998	CcSEcCtD
Dasatinib—Rash—Simvastatin—atherosclerosis	0.000129	0.000991	CcSEcCtD
Dasatinib—Dermatitis—Simvastatin—atherosclerosis	0.000129	0.00099	CcSEcCtD
Dasatinib—Diarrhoea—Niacin—atherosclerosis	0.000129	0.000988	CcSEcCtD
Dasatinib—Headache—Simvastatin—atherosclerosis	0.000128	0.000985	CcSEcCtD
Dasatinib—Nausea—Ezetimibe—atherosclerosis	0.000128	0.000979	CcSEcCtD
Dasatinib—Diarrhoea—Pravastatin—atherosclerosis	0.000127	0.000973	CcSEcCtD
Dasatinib—Dizziness—Niacin—atherosclerosis	0.000124	0.000955	CcSEcCtD
Dasatinib—Dizziness—Pravastatin—atherosclerosis	0.000123	0.00094	CcSEcCtD
Dasatinib—Nausea—Simvastatin—atherosclerosis	0.000122	0.000934	CcSEcCtD
Dasatinib—Vomiting—Niacin—atherosclerosis	0.00012	0.000918	CcSEcCtD
Dasatinib—Rash—Niacin—atherosclerosis	0.000119	0.00091	CcSEcCtD
Dasatinib—Dermatitis—Niacin—atherosclerosis	0.000119	0.000909	CcSEcCtD
Dasatinib—Headache—Niacin—atherosclerosis	0.000118	0.000904	CcSEcCtD
Dasatinib—Vomiting—Pravastatin—atherosclerosis	0.000118	0.000904	CcSEcCtD
Dasatinib—Rash—Pravastatin—atherosclerosis	0.000117	0.000896	CcSEcCtD
Dasatinib—Dermatitis—Pravastatin—atherosclerosis	0.000117	0.000895	CcSEcCtD
Dasatinib—Headache—Pravastatin—atherosclerosis	0.000116	0.000891	CcSEcCtD
Dasatinib—Nausea—Niacin—atherosclerosis	0.000112	0.000858	CcSEcCtD
Dasatinib—Nausea—Pravastatin—atherosclerosis	0.00011	0.000844	CcSEcCtD
Dasatinib—ABCG2—liver—atherosclerosis	0.00011	0.00144	CbGeAlD
Dasatinib—CYP1A2—liver—atherosclerosis	0.000106	0.00139	CbGeAlD
Dasatinib—CYP1A1—liver—atherosclerosis	0.000104	0.00137	CbGeAlD
Dasatinib—CYP3A5—liver—atherosclerosis	0.000102	0.00134	CbGeAlD
Dasatinib—ABCB1—cardiovascular system—atherosclerosis	8.76e-05	0.00115	CbGeAlD
Dasatinib—ABCB1—adipose tissue—atherosclerosis	7.73e-05	0.00101	CbGeAlD
Dasatinib—CYP3A4—liver—atherosclerosis	7.66e-05	0.001	CbGeAlD
Dasatinib—ABCB1—liver—atherosclerosis	5.42e-05	0.00071	CbGeAlD
Dasatinib—YES1—Signaling Pathways—MAPK3—atherosclerosis	1.33e-06	7.72e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—F2—atherosclerosis	1.33e-06	7.71e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—MAPK3—atherosclerosis	1.32e-06	7.69e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MMP9—atherosclerosis	1.32e-06	7.68e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—APOE—atherosclerosis	1.32e-06	7.67e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CXCL8—atherosclerosis	1.32e-06	7.65e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—STAT3—atherosclerosis	1.31e-06	7.63e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PPARA—atherosclerosis	1.31e-06	7.63e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IGF1—atherosclerosis	1.31e-06	7.63e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—NFKB1—atherosclerosis	1.31e-06	7.6e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—CAV1—atherosclerosis	1.31e-06	7.6e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—APOA1—atherosclerosis	1.3e-06	7.58e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—HMOX1—atherosclerosis	1.3e-06	7.55e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—NFKB1—atherosclerosis	1.29e-06	7.52e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CXCL8—atherosclerosis	1.29e-06	7.49e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TGFB1—atherosclerosis	1.29e-06	7.49e-06	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—AKT1—atherosclerosis	1.29e-06	7.48e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MAPK8—atherosclerosis	1.29e-06	7.47e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—TGFB1—atherosclerosis	1.28e-06	7.46e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—MAPK8—atherosclerosis	1.27e-06	7.39e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—AGT—atherosclerosis	1.27e-06	7.39e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PIK3CG—atherosclerosis	1.27e-06	7.38e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—IL6—atherosclerosis	1.27e-06	7.38e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CXCL8—atherosclerosis	1.27e-06	7.37e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PTGS2—atherosclerosis	1.26e-06	7.33e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—MAPK3—atherosclerosis	1.26e-06	7.29e-06	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—IL6—atherosclerosis	1.25e-06	7.29e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—VEGFA—atherosclerosis	1.25e-06	7.28e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—SERPINE1—atherosclerosis	1.25e-06	7.25e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—APOE—atherosclerosis	1.25e-06	7.24e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—APOB—atherosclerosis	1.24e-06	7.23e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—STAT3—atherosclerosis	1.24e-06	7.21e-06	CbGpPWpGaD
Dasatinib—KIT—Disease—IL6—atherosclerosis	1.24e-06	7.19e-06	CbGpPWpGaD
Dasatinib—KIT—Immune System—AKT1—atherosclerosis	1.24e-06	7.19e-06	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—AKT1—atherosclerosis	1.24e-06	7.18e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—CAV1—atherosclerosis	1.24e-06	7.18e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—APOA1—atherosclerosis	1.23e-06	7.16e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	1.22e-06	7.11e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CXCL8—atherosclerosis	1.22e-06	7.1e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—STAT3—atherosclerosis	1.21e-06	7.05e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—GSTM1—atherosclerosis	1.21e-06	7.03e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ABCA1—atherosclerosis	1.21e-06	7.02e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—NAMPT—atherosclerosis	1.21e-06	7.01e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CXCL8—atherosclerosis	1.21e-06	7.01e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—INS—atherosclerosis	1.2e-06	6.99e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—LIPC—atherosclerosis	1.2e-06	6.97e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—APOC3—atherosclerosis	1.19e-06	6.93e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—NOS3—atherosclerosis	1.19e-06	6.92e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3CG—atherosclerosis	1.19e-06	6.92e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MMP9—atherosclerosis	1.19e-06	6.92e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—LPL—atherosclerosis	1.19e-06	6.9e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—VEGFA—atherosclerosis	1.19e-06	6.9e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—MAPK3—atherosclerosis	1.19e-06	6.89e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—LDLR—atherosclerosis	1.18e-06	6.88e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CCL2—atherosclerosis	1.18e-06	6.87e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—NFKB1—atherosclerosis	1.18e-06	6.84e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—STAT3—atherosclerosis	1.18e-06	6.83e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—IL6—atherosclerosis	1.17e-06	6.81e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—AKT1—atherosclerosis	1.17e-06	6.8e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MMP9—atherosclerosis	1.17e-06	6.77e-06	CbGpPWpGaD
Dasatinib—JAK2—GPCR downstream signaling—AKT1—atherosclerosis	1.17e-06	6.77e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—STAT3—atherosclerosis	1.16e-06	6.76e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IGF1—atherosclerosis	1.16e-06	6.76e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—MAPK3—atherosclerosis	1.16e-06	6.73e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—GPX1—atherosclerosis	1.16e-06	6.73e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MAPK8—atherosclerosis	1.16e-06	6.73e-06	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—AKT1—atherosclerosis	1.16e-06	6.73e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CETP—atherosclerosis	1.16e-06	6.72e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—NFKB1—atherosclerosis	1.15e-06	6.7e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TGFB1—atherosclerosis	1.15e-06	6.69e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PPARG—atherosclerosis	1.15e-06	6.68e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MMP9—atherosclerosis	1.15e-06	6.67e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—IL6—atherosclerosis	1.15e-06	6.67e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—IL6—atherosclerosis	1.15e-06	6.66e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—IL6—atherosclerosis	1.14e-06	6.65e-06	CbGpPWpGaD
Dasatinib—KIT—Disease—AKT1—atherosclerosis	1.14e-06	6.64e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—NFKB1—atherosclerosis	1.14e-06	6.6e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MAPK8—atherosclerosis	1.13e-06	6.59e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CD36—atherosclerosis	1.13e-06	6.56e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—INS—atherosclerosis	1.13e-06	6.55e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CG—atherosclerosis	1.13e-06	6.54e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—TGFB1—atherosclerosis	1.12e-06	6.53e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MAPK3—atherosclerosis	1.12e-06	6.52e-06	CbGpPWpGaD
Dasatinib—LYN—Immune System—IL6—atherosclerosis	1.12e-06	6.51e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MAPK8—atherosclerosis	1.12e-06	6.49e-06	CbGpPWpGaD
Dasatinib—ABL1—Immune System—IL6—atherosclerosis	1.11e-06	6.48e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—MAPK3—atherosclerosis	1.11e-06	6.46e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—SCARB1—atherosclerosis	1.11e-06	6.44e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—IL6—atherosclerosis	1.11e-06	6.43e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MMP9—atherosclerosis	1.11e-06	6.42e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—SERPINE1—atherosclerosis	1.1e-06	6.42e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—IL6—atherosclerosis	1.1e-06	6.41e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—NFKB1—atherosclerosis	1.09e-06	6.35e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MMP9—atherosclerosis	1.09e-06	6.34e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TGFB1—atherosclerosis	1.09e-06	6.33e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PPARG—atherosclerosis	1.09e-06	6.31e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—AKT1—atherosclerosis	1.08e-06	6.28e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—NFKB1—atherosclerosis	1.08e-06	6.27e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MAPK8—atherosclerosis	1.07e-06	6.24e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—STAT3—atherosclerosis	1.07e-06	6.24e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—MTHFR—atherosclerosis	1.07e-06	6.21e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—VEGFA—atherosclerosis	1.07e-06	6.21e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—INS—atherosclerosis	1.07e-06	6.19e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—IL6—atherosclerosis	1.06e-06	6.17e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MAPK8—atherosclerosis	1.06e-06	6.16e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—STAT3—atherosclerosis	1.06e-06	6.15e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—AKT1—atherosclerosis	1.06e-06	6.15e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—AKT1—atherosclerosis	1.06e-06	6.15e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CXCL8—atherosclerosis	1.06e-06	6.14e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—IL6—atherosclerosis	1.06e-06	6.14e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—AKT1—atherosclerosis	1.06e-06	6.13e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—NOS3—atherosclerosis	1.05e-06	6.13e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PPARA—atherosclerosis	1.05e-06	6.1e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—IL6—atherosclerosis	1.05e-06	6.09e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—VEGFA—atherosclerosis	1.05e-06	6.08e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—HMGCR—atherosclerosis	1.05e-06	6.08e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—HMOX1—atherosclerosis	1.04e-06	6.02e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—STAT3—atherosclerosis	1.04e-06	6.02e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—ALB—atherosclerosis	1.03e-06	6e-06	CbGpPWpGaD
Dasatinib—LYN—Immune System—AKT1—atherosclerosis	1.03e-06	6e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—VEGFA—atherosclerosis	1.03e-06	5.99e-06	CbGpPWpGaD
Dasatinib—ABL1—Immune System—AKT1—atherosclerosis	1.03e-06	5.97e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—MAPK3—atherosclerosis	1.03e-06	5.96e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—AKT1—atherosclerosis	1.02e-06	5.93e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—STAT3—atherosclerosis	1.02e-06	5.93e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—IL6—atherosclerosis	1.02e-06	5.91e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—AKT1—atherosclerosis	1.02e-06	5.91e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—AGT—atherosclerosis	1.02e-06	5.9e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MAPK3—atherosclerosis	1.01e-06	5.88e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—APOE—atherosclerosis	9.96e-07	5.79e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—TGFB1—atherosclerosis	9.96e-07	5.78e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—APOB—atherosclerosis	9.93e-07	5.77e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—VEGFA—atherosclerosis	9.92e-07	5.77e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MAPK3—atherosclerosis	9.9e-07	5.75e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—NOS3—atherosclerosis	9.89e-07	5.74e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CAV1—atherosclerosis	9.87e-07	5.73e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—APOA1—atherosclerosis	9.84e-07	5.72e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—STAT3—atherosclerosis	9.83e-07	5.71e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TGFB1—atherosclerosis	9.81e-07	5.7e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—VEGFA—atherosclerosis	9.8e-07	5.69e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—AKT1—atherosclerosis	9.79e-07	5.69e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—ALB—atherosclerosis	9.76e-07	5.67e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MAPK3—atherosclerosis	9.75e-07	5.66e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—AKT1—atherosclerosis	9.74e-07	5.66e-06	CbGpPWpGaD
Dasatinib—MAPK14—Gene Expression—AKT1—atherosclerosis	9.74e-07	5.66e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—IL6—atherosclerosis	9.71e-07	5.64e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—STAT3—atherosclerosis	9.7e-07	5.64e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—IL6—atherosclerosis	9.68e-07	5.62e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—AKT1—atherosclerosis	9.67e-07	5.62e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GSTM1—atherosclerosis	9.66e-07	5.61e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TGFB1—atherosclerosis	9.61e-07	5.58e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MMP9—atherosclerosis	9.56e-07	5.55e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—LPL—atherosclerosis	9.48e-07	5.51e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TGFB1—atherosclerosis	9.46e-07	5.5e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—NFKB1—atherosclerosis	9.45e-07	5.49e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—AKT1—atherosclerosis	9.39e-07	5.46e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MAPK3—atherosclerosis	9.39e-07	5.45e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CXCL8—atherosclerosis	9.35e-07	5.43e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—NOS3—atherosclerosis	9.34e-07	5.43e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ABCA1—atherosclerosis	9.33e-07	5.42e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MAPK8—atherosclerosis	9.29e-07	5.4e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MAPK3—atherosclerosis	9.27e-07	5.38e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GPX1—atherosclerosis	9.25e-07	5.38e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—IL6—atherosclerosis	9.18e-07	5.33e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TGFB1—atherosclerosis	9.11e-07	5.29e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PTGS2—atherosclerosis	9.04e-07	5.25e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CD36—atherosclerosis	9.01e-07	5.24e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TGFB1—atherosclerosis	8.99e-07	5.22e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CG—atherosclerosis	8.99e-07	5.22e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—AKT1—atherosclerosis	8.96e-07	5.2e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—AKT1—atherosclerosis	8.93e-07	5.19e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PPARG—atherosclerosis	8.67e-07	5.04e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—IL6—atherosclerosis	8.67e-07	5.04e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—VEGFA—atherosclerosis	8.58e-07	4.99e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PTGS2—atherosclerosis	8.54e-07	4.96e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—MTHFR—atherosclerosis	8.54e-07	4.96e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—INS—atherosclerosis	8.51e-07	4.94e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—STAT3—atherosclerosis	8.5e-07	4.94e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—IL6—atherosclerosis	8.47e-07	4.92e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—AKT1—atherosclerosis	8.47e-07	4.92e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MMP9—atherosclerosis	8.46e-07	4.91e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PPARA—atherosclerosis	8.38e-07	4.87e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—NFKB1—atherosclerosis	8.37e-07	4.86e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MAPK8—atherosclerosis	8.23e-07	4.78e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—IL6—atherosclerosis	8.21e-07	4.77e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—IL6—atherosclerosis	8.13e-07	4.72e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MAPK3—atherosclerosis	8.12e-07	4.72e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—AGT—atherosclerosis	8.11e-07	4.71e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—HMOX1—atherosclerosis	8e-07	4.65e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—AKT1—atherosclerosis	8e-07	4.65e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—APOE—atherosclerosis	7.95e-07	4.62e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CAV1—atherosclerosis	7.88e-07	4.58e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TGFB1—atherosclerosis	7.88e-07	4.58e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—APOA1—atherosclerosis	7.86e-07	4.57e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—AKT1—atherosclerosis	7.82e-07	4.54e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—ALB—atherosclerosis	7.8e-07	4.53e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—APOB—atherosclerosis	7.67e-07	4.45e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—VEGFA—atherosclerosis	7.6e-07	4.41e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—AKT1—atherosclerosis	7.57e-07	4.4e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—STAT3—atherosclerosis	7.52e-07	4.37e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—IL6—atherosclerosis	7.5e-07	4.36e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—AKT1—atherosclerosis	7.5e-07	4.36e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—NOS3—atherosclerosis	7.46e-07	4.33e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GSTM1—atherosclerosis	7.46e-07	4.33e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IL6—atherosclerosis	7.39e-07	4.3e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—LPL—atherosclerosis	7.32e-07	4.25e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IL6—atherosclerosis	7.24e-07	4.21e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MAPK3—atherosclerosis	7.19e-07	4.17e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CG—atherosclerosis	7.17e-07	4.17e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GPX1—atherosclerosis	7.14e-07	4.15e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IL6—atherosclerosis	7.13e-07	4.14e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TGFB1—atherosclerosis	6.97e-07	4.05e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—AKT1—atherosclerosis	6.97e-07	4.05e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CD36—atherosclerosis	6.95e-07	4.04e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PPARG—atherosclerosis	6.92e-07	4.02e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—AKT1—atherosclerosis	6.92e-07	4.02e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IL6—atherosclerosis	6.86e-07	3.99e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PTGS2—atherosclerosis	6.82e-07	3.96e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—AKT1—atherosclerosis	6.82e-07	3.96e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—INS—atherosclerosis	6.79e-07	3.95e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IL6—atherosclerosis	6.78e-07	3.94e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—AKT1—atherosclerosis	6.68e-07	3.88e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—MTHFR—atherosclerosis	6.59e-07	3.83e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—AKT1—atherosclerosis	6.58e-07	3.82e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PPARA—atherosclerosis	6.46e-07	3.76e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—AKT1—atherosclerosis	6.34e-07	3.69e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—AKT1—atherosclerosis	6.33e-07	3.68e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—AGT—atherosclerosis	6.26e-07	3.64e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—AKT1—atherosclerosis	6.25e-07	3.63e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—ALB—atherosclerosis	6.23e-07	3.62e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—APOE—atherosclerosis	6.13e-07	3.56e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CAV1—atherosclerosis	6.08e-07	3.53e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—APOA1—atherosclerosis	6.06e-07	3.52e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—NOS3—atherosclerosis	5.96e-07	3.46e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IL6—atherosclerosis	5.93e-07	3.45e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CG—atherosclerosis	5.54e-07	3.22e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—AKT1—atherosclerosis	5.47e-07	3.18e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PTGS2—atherosclerosis	5.45e-07	3.16e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PPARG—atherosclerosis	5.34e-07	3.1e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL6—atherosclerosis	5.25e-07	3.05e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—INS—atherosclerosis	5.24e-07	3.05e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—AKT1—atherosclerosis	4.85e-07	2.82e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—ALB—atherosclerosis	4.8e-07	2.79e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—NOS3—atherosclerosis	4.6e-07	2.67e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—AKT1—atherosclerosis	4.54e-07	2.64e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—AKT1—atherosclerosis	4.29e-07	2.49e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTGS2—atherosclerosis	4.2e-07	2.44e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—AKT1—atherosclerosis	3.43e-07	1.99e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—AKT1—atherosclerosis	2.74e-07	1.59e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—AKT1—atherosclerosis	2.11e-07	1.23e-06	CbGpPWpGaD
